Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18638229 | BCMA CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF | April 2024 | January 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18637283 | ADJUVANT TREATMENT OF HER2-POSITIVE BREAST CANCER | April 2024 | September 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18593711 | SYSTEMS TARGETING PSMA AND CA9 | March 2024 | January 2025 | Allow | 10 | 0 | 1 | Yes | No |
| 18409450 | GOUT FLARE PREVENTION METHODS USING IL-1BETA BLOCKERS | January 2024 | November 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18514019 | Cancer Cytotoxic Exosome Formulations and Methods for Use in Treating Cancer | November 2023 | June 2025 | Allow | 19 | 2 | 0 | Yes | No |
| 18490581 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST NON-SMALL CELL LUNG CANCER AND OTHER CANCERS | October 2023 | August 2024 | Allow | 10 | 1 | 0 | Yes | No |
| 18466103 | MAGE-A4 PEPTIDE DUAL T CELL ENGAGERS | September 2023 | July 2024 | Allow | 10 | 1 | 1 | Yes | No |
| 18323013 | DUAL CONJUGATION PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES | May 2023 | May 2025 | Allow | 23 | 0 | 0 | Yes | No |
| 18295645 | RECOMBINANT POLYCLONAL PROTEINS TARGETING COVID-19 AND METHODS OF USE THEREOF | April 2023 | April 2025 | Allow | 25 | 0 | 0 | Yes | No |
| 17933088 | HIGH AVIDITY ANTIGEN RECOGNIZING CONSTRUCTS | September 2022 | March 2025 | Allow | 30 | 0 | 1 | Yes | No |
| 17875723 | ANTI-LY6H ANTIBODIES AND ANTIBODY DRUG CONJUGATES | July 2022 | January 2025 | Allow | 29 | 0 | 0 | Yes | No |
| 17746740 | PHOTOSENSITIZING ANTIBODY-FLUOROPHORE CONJUGATES | May 2022 | January 2025 | Allow | 32 | 1 | 0 | No | No |
| 17730149 | AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS | April 2022 | February 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17701436 | TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY | March 2022 | February 2025 | Allow | 35 | 1 | 1 | No | No |
| 17666143 | Cancer Detection Method | February 2022 | February 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17573870 | Caninized Antibodies | January 2022 | November 2024 | Allow | 34 | 1 | 0 | Yes | No |
| 17553941 | ADAM9-Binding Molecules, and Methods of Use Thereof | December 2021 | December 2024 | Abandon | 36 | 1 | 0 | Yes | No |
| 17616755 | PURIFIED DOUBLE NEGATIVE T CELL AND PREPARATION AND USE THEREOF | December 2021 | May 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17531477 | MODULATION OF CANCER IMMUNITY WITH TYPE 2 INNATE LYMPHOID CELLS, INTERLEUKIN 33, AND/OR INTERFERON INDUCED PROTEIN 44 | November 2021 | June 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17606847 | Anti-human ephrin B1 antibodies and uses thereof | October 2021 | June 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17601765 | ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR WHICH TARGETS CLAUDIN 18.2 | October 2021 | February 2025 | Allow | 41 | 1 | 0 | Yes | No |
| 17470462 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER | September 2021 | December 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17463156 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | August 2021 | March 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17459905 | B1SP Fusion Protein Therapeutics, Methods, and Uses | August 2021 | April 2025 | Allow | 43 | 2 | 1 | Yes | No |
| 17434225 | NEW BIOMARKERS AND BIOTARGETS IN RENAL CELL CARCINOMA | August 2021 | March 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17430938 | T CELL RECEPTORS SPECIFIC TO B-CELL MATURATION ANTIGEN FOR TREATMENT OF CANCER | August 2021 | June 2025 | Allow | 46 | 2 | 1 | Yes | No |
| 17361477 | USE OF LEUKEMIA-DERIVED CELLS IN OVARIAN CANCER VACCINES | June 2021 | March 2025 | Allow | 45 | 2 | 1 | Yes | Yes |
| 17296415 | PREDICTING A TREATMENT RESPONSE IN INFLAMMATORY BOWEL DISEASE | May 2021 | May 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17329057 | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 | May 2021 | December 2024 | Abandon | 42 | 2 | 0 | No | No |
| 17292182 | HUMANIZED ANTI-SIRP ALPHA ANTIBODIES | May 2021 | September 2024 | Allow | 40 | 2 | 0 | Yes | No |
| 17285861 | USE OF ANTI-FAM19A5 ANTIBODIES | April 2021 | July 2025 | Allow | 51 | 3 | 1 | No | No |
| 17284188 | TREATMENT WITH HIGHLY SIAYLATED IGG COMPOSITIONS | April 2021 | June 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17283786 | BINDING PROTEINS SPECIFIC FOR HA-1H AND USES THEREOF | April 2021 | June 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17282325 | LEUCINE-RICH ALPHA2 GLYCOPROTEIN COMPOSITION | April 2021 | March 2025 | Allow | 48 | 1 | 1 | Yes | No |
| 17276276 | HIGHLY EFFICIENT ANTI-TFPI ANTIBODY COMPOSITION | March 2021 | November 2024 | Allow | 44 | 2 | 0 | No | No |
| 17269615 | SENSITIVITY MARKER FOR ANTIBODY-DRUG CONJUGATE | February 2021 | February 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17257553 | COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY TARGETING FLT3, PD-1, AND/OR PD-L1 | December 2020 | December 2024 | Abandon | 47 | 1 | 1 | No | No |
| 17256788 | CD6 TARGETED CHIMERIC ANTIGEN RECEPTORS FOR TREATMENT OF CERTAIN AUTOIMMUNE DISORDERS | December 2020 | December 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 17129413 | MODULATORS OF ROR1-ROR2 BINDING | December 2020 | December 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16972555 | METHODS AND MEANS FOR ATTRACTING IMMUNE EFFECTOR CELLS TO TUMOR CELLS | December 2020 | June 2025 | Abandon | 54 | 2 | 1 | Yes | No |
| 17111453 | HUMAN CGRP RECEPTOR BINDING PROTEINS | December 2020 | July 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 16950758 | POLYPEPTIDES | November 2020 | August 2024 | Allow | 45 | 2 | 1 | Yes | No |
| 17033441 | METHODS OF USING BISPECIFIC ANTIGEN-BINDING CONSTRUCTS TARGETING HER2 | September 2020 | July 2024 | Allow | 46 | 2 | 0 | Yes | Yes |
| 16979102 | METHOD AND COMPOSITION FOR TREATING TUMORS | September 2020 | August 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 16994953 | PSMA and CD3 Bispecific T Cell Engaging Antibody Constructs | August 2020 | May 2025 | Allow | 57 | 5 | 1 | Yes | No |
| 16970114 | RESCUING CANCER PATIENTS FROM RESISTANCE TO TREATMENT WITH INHIBITORS OF PD-1/PD-L1 INTERACTIONS | August 2020 | October 2024 | Allow | 50 | 2 | 1 | Yes | No |
| 16348793 | KIT FOR DETECTING SUBSET OF HUMAN REGULATORY T CELL, AND DETECTION METHOD THEREOF | May 2020 | December 2024 | Abandon | 60 | 1 | 2 | No | No |
| 16857394 | METHODS OF MANUFACTURING ALLOGENEIC CAR T CELLS | April 2020 | July 2024 | Allow | 51 | 3 | 1 | Yes | No |
| 16783238 | MARKERS FOR THE DIAGNOSIS OF BIOCHEMICAL RECURRENCE IN PROSTATE CANCER | February 2020 | January 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16732557 | Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers | January 2020 | December 2024 | Abandon | 59 | 5 | 1 | No | No |
| 16626683 | METHOD FOR PREDICTING EFFECT OF TUMOR IMMUNOTHERAPY USING TUMOR CYTOTOXIC ACTIVITY OF PERIPHERAL BLOOD T CELLS AS INDEX | December 2019 | November 2024 | Allow | 59 | 4 | 1 | Yes | No |
| 16476239 | COMBINED TREATMENT WITH NETRIN-1 INTERFERING DRUG AND IMMUNE CHECKPOINT INHIBITORS DRUGS | July 2019 | July 2024 | Allow | 60 | 3 | 1 | Yes | Yes |
| 16329125 | ADENOVIRUS ARMED WITH BISPECIFIC T CELL ENGAGER | February 2019 | November 2024 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16271153 | TREATMENT OF CANCER USING A COMBINATION OF IMMUNOMODULATION AND CHECK POINT INHIBITORS | February 2019 | February 2025 | Abandon | 60 | 7 | 0 | No | No |
| 16094737 | AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF | October 2018 | August 2023 | Allow | 58 | 4 | 1 | Yes | Yes |
| 15666171 | METHOD OF ASSAYING APOLIPOPROTEIN AI FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER | August 2017 | October 2019 | Allow | 27 | 1 | 1 | Yes | No |
| 15407890 | Cancer Vaccines | January 2017 | January 2019 | Allow | 24 | 1 | 1 | Yes | No |
| 15363045 | ANTI-LGR5 ANTIBODIES AND USES THEREOF | November 2016 | January 2019 | Allow | 26 | 1 | 1 | Yes | No |
| 15341729 | LOX AND LOXL2 INHIBITORS AND USES THEREOF | November 2016 | July 2019 | Allow | 33 | 3 | 0 | Yes | No |
| 15214220 | ANTIBODY AGAINST THE CSF-1R | July 2016 | January 2018 | Allow | 18 | 2 | 0 | No | No |
| 15034350 | Human Neutralizing Anti-Kit Antibodies and Uses Thereof | May 2016 | November 2017 | Allow | 19 | 2 | 1 | Yes | No |
| 14985190 | METHODS FOR PREDICTING AND IMPROVING THE SURVIVAL OF COLORECTAL CANCER PATIENTS | December 2015 | October 2017 | Allow | 21 | 1 | 1 | Yes | No |
| 14967475 | PHARMACEUTICAL COMPOSITIONS CONTAINING sc(Fv)2 | December 2015 | June 2017 | Allow | 18 | 2 | 0 | No | No |
| 14869316 | COMPOSITIONS AND METHODS FOR DETECTING ORAL NEOPLASM | September 2015 | January 2018 | Allow | 27 | 2 | 1 | Yes | No |
| 14655119 | INHIBITION OF CANCER GROWTH AND METASTASIS | June 2015 | October 2017 | Allow | 27 | 2 | 1 | Yes | No |
| 14709511 | VEGFR2/ANG2 COMPOUNDS | May 2015 | October 2016 | Allow | 17 | 0 | 1 | Yes | No |
| 14684945 | ANTI-PHOSPHO-AKT ANTIBODIES | April 2015 | September 2015 | Allow | 5 | 0 | 0 | Yes | No |
| 14665697 | MULTISPECIFIC ANTIBODIES | March 2015 | August 2016 | Allow | 17 | 1 | 0 | Yes | No |
| 14566501 | Saposin C-DOPS: A Novel Anti-Tumor Agent | December 2014 | September 2018 | Allow | 45 | 3 | 1 | Yes | Yes |
| 14525783 | DOT1 Histone Methyltransferases as a Target for Identifying Therapeutic Agents for Leukemia | October 2014 | August 2016 | Allow | 22 | 2 | 0 | Yes | No |
| 14374869 | MONOCYTE BIOMARKERS FOR CANCER DETECTION | July 2014 | March 2018 | Allow | 44 | 4 | 1 | Yes | No |
| 14329496 | ANTIBODIES THAT RECOGNIZE IAPP | July 2014 | August 2017 | Allow | 37 | 1 | 1 | Yes | No |
| 14329475 | ANTIBODIES THAT RECOGNIZE IAPP | July 2014 | November 2017 | Allow | 40 | 1 | 1 | Yes | No |
| 14148161 | METHOD FOR THE PRODUCTION OF AN IMMUNOSTIMULATING MUCIN (MUC1) | January 2014 | June 2016 | Allow | 30 | 2 | 1 | Yes | No |
| 14045019 | TREATMENT OF TUMORS USING SPECIFIC ANTI-L1 ANTIBODY | October 2013 | December 2015 | Allow | 26 | 1 | 1 | Yes | No |
| 14025875 | NOVEL ANTI-CXCR4 ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER | September 2013 | November 2015 | Allow | 26 | 1 | 0 | No | No |
| 13932285 | ANTIBODY AGAINST THE CSF-1R | July 2013 | August 2015 | Allow | 26 | 1 | 0 | Yes | No |
| 13825760 | BIOMARKERS FOR DETERMINING BREAST CANCER BONE METASTASIS | June 2013 | April 2016 | Allow | 36 | 2 | 1 | Yes | No |
| 13897587 | Antibodies and Immunotoxins that Target Human Glycoprotein NMB | May 2013 | May 2015 | Allow | 24 | 0 | 0 | Yes | No |
| 13888293 | LOX AND LOXL2 INHIBITORS AND USES THEREOF | May 2013 | August 2015 | Allow | 27 | 1 | 0 | Yes | No |
| 13742537 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY | January 2013 | August 2017 | Allow | 55 | 5 | 1 | Yes | No |
| 13643221 | NEWLY IDENTIFIED COLON CANCER MARKER AND DIAGNOSTIC KIT USING THE SAME | December 2012 | May 2015 | Allow | 30 | 1 | 1 | Yes | No |
| 13673565 | ANTI-FcRH5 ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | November 2012 | December 2014 | Allow | 25 | 0 | 1 | Yes | No |
| 13626393 | PROTEIN SCAFFOLDS FOR TARGETED DELIVERY OF TOXIC IRON TO CANCER CELLS | September 2012 | January 2016 | Allow | 40 | 4 | 1 | Yes | No |
| 13486434 | Compositions and Methods for Preventing or Treating Cancer | June 2012 | October 2013 | Allow | 16 | 1 | 1 | Yes | No |
| 13470965 | SMOOTHENED POLYPEPTIDES AND METHODS OF USE | May 2012 | May 2013 | Allow | 12 | 1 | 1 | Yes | No |
| 13392548 | HUMANIZED ANTIBODIES SPECIFIC FOR HSP65-DERIVED PEPTIDE-6 METHODS AND USES THEREOF | February 2012 | November 2013 | Allow | 20 | 1 | 1 | Yes | No |
| 13367178 | TREATMENT OF TUMORS USING SPECIFIC ANTI-L1 ANTIBODY | February 2012 | July 2013 | Allow | 17 | 1 | 1 | Yes | No |
| 13339247 | METHODS FOR DIAGNOSIS AND TREATMENT OF ENDOMETRIAL CANCER | December 2011 | April 2015 | Allow | 39 | 4 | 1 | Yes | No |
| 13300134 | REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY | November 2011 | November 2012 | Allow | 12 | 1 | 0 | Yes | No |
| 13373367 | Methods for the treatment of tumors expressing TAT123 or naturally occurring variants thereof | November 2011 | November 2013 | Allow | 25 | 1 | 0 | Yes | No |
| 13209285 | USE OF ANTIBODIES FOR THE VACCINATION AGAINST CANCER | August 2011 | January 2013 | Allow | 17 | 1 | 0 | Yes | No |
| 13207705 | Anti-Tenascin-C A2 Antibodies and Methods of Use | August 2011 | May 2015 | Allow | 46 | 3 | 1 | Yes | Yes |
| 13121447 | IMMUNOGENIC PEPTIDES | June 2011 | April 2013 | Allow | 24 | 1 | 1 | Yes | No |
| 13159015 | METHOD OF TREATING CANCER AND/OR CELLULAR PROLIFERATIVE CONDITIONS AND AGENTS TARGETING HYALURONAN ANABOLISM USEFUL FOR SAME | June 2011 | April 2013 | Allow | 22 | 1 | 1 | Yes | No |
| 13058113 | Methods for Predicting the Response to Anti-Cancer Treatment with an Agonist of TLR7 or an Agonist of TLR8 | April 2011 | February 2014 | Allow | 37 | 2 | 1 | Yes | No |
| 12988135 | ANTI-AREG/HB-EGF ANTIBODIES AND TREATMENT | March 2011 | May 2014 | Allow | 43 | 2 | 1 | Yes | No |
| 12993656 | Compositions and Methods for Diagnosing and Treating Cancer | February 2011 | February 2013 | Allow | 26 | 1 | 1 | Yes | No |
| 13021202 | NUCLEIC ACIDS AND CORRESPONDING PROTEINS ENTITLED 202P5A5 USEFUL IN TREATMENT AND DETECTION OF CANCER | February 2011 | October 2012 | Allow | 21 | 1 | 1 | No | No |
| 12983738 | MATERIALS AND METHOD FOR ASSAYING FOR METHYLATION OF CpG ISLANDS ASSOCIATED WITH GENES IN THE EVALUATION OF CANCER | January 2011 | May 2013 | Allow | 28 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SANG, HONG.
With a 66.7% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 29.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SANG, HONG works in Art Unit 1646 and has examined 182 patent applications in our dataset. With an allowance rate of 88.5%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 40 months.
Examiner SANG, HONG's allowance rate of 88.5% places them in the 65% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by SANG, HONG receive 2.05 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SANG, HONG is 40 months. This places the examiner in the 7% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +23.0% benefit to allowance rate for applications examined by SANG, HONG. This interview benefit is in the 73% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 29.9% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 68.1% of cases where such amendments are filed. This entry rate is in the 89% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 133.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 84% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.
This examiner withdraws rejections or reopens prosecution in 87.0% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 75.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 69.2% are granted (fully or in part). This grant rate is in the 86% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 12.6% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.